<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39336455</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1648-9144</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>29</Day></PubDate></JournalIssue><Title>Medicina (Kaunas, Lithuania)</Title><ISOAbbreviation>Medicina (Kaunas)</ISOAbbreviation></Journal><ArticleTitle>Hypochloremia: A Potential Indicator of Poor Outcomes in COVID-19.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1414</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/medicina60091414</ELocationID><Abstract><AbstractText><i>Background: Coronavirus</i> Disease-2019 (COVID-19) has posed formidable challenges to healthcare systems. Exploring novel biomarkers that can provide valuable prognostic insights, particularly in critically ill patients, has a significant importance. Against this backdrop, our study aims to elucidate the associations between serum chloride levels and clinical outcomes. <i>Methods:</i> A total of 499 patients were enrolled into the study. The serum chloride levels of patients upon hospital admission were recorded and then categorized into three groups (hypochloremia, normochloremia, and hyperchloremia) for the evaluation of clinical outcomes. Additionally, serum C-reactive protein, procalcitonin, and D-dimer measurements were recorded for further evaluation. <i>Results:</i> A total of 390 (78.1%) patients tested positive for COVID-19 via polymerase chain reaction testing. Non-contrast thorax computed tomography scans were indicative of COVID-19 compatibility for all patients. A total of 210 (42%) patients were female and 289 (58%) were male. A total of 214 (42.8%) patients necessitated tocilizumab intervention; 250 (50.1%) were at an intensive care unit (ICU), with 166 (66.4%) of them receiving tocilizumab. A total of 65 (13%) patients died, 40 (61.5%) of whom received tocilizumab; 41 (63%) were in the ICU. Serum chloride levels upon admission were markedly lower and elevated D-dimer levels were apparent in tocilizumab users, patients requiring ICU care, and patients who died. <i>Conclusions:</i> our findings provide robust evidence supporting the value of serum chloride levels as a prognostic biomarker in critically ill COVID-19 patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barkay</LastName><ForeName>Orçun</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-5347-7740</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan 24100, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karakeçili</LastName><ForeName>Faruk</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-7368-7187</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan 24100, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Medicina (Kaunas)</MedlineTA><NlmUniqueID>9425208</NlmUniqueID><ISSNLinking>1010-660X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002712">Chlorides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005338">Fibrin Fibrinogen Degradation Products</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C036309">fibrin fragment D</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077740">Procalcitonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002712" MajorTopicYN="Y">Chlorides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005338" MajorTopicYN="Y">Fibrin Fibrinogen Degradation Products</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077740" MajorTopicYN="N">Procalcitonin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">D-dimer</Keyword><Keyword MajorTopicYN="N">ICU</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">hypochloremia</Keyword><Keyword MajorTopicYN="N">tocilizumab</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39336455</ArticleId><ArticleId IdType="pmc">PMC11434189</ArticleId><ArticleId IdType="doi">10.3390/medicina60091414</ArticleId><ArticleId IdType="pii">medicina60091414</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sharma A., Tiwari S., Deb M.K., Marty J.L. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): A global pandemic and treatment strategies. Int. J. Antimicrob. Agents. 2020;56:106054. doi: 10.1016/j.ijantimicag.2020.106054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.106054</ArticleId><ArticleId IdType="pmc">PMC7286265</ArticleId><ArticleId IdType="pubmed">32534188</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Qahtani A.A. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Emergence, history, basic and clinical aspects. Saudi J. Biol. Sci. 2020;27:2531–2538. doi: 10.1016/j.sjbs.2020.04.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sjbs.2020.04.033</ArticleId><ArticleId IdType="pmc">PMC7179492</ArticleId><ArticleId IdType="pubmed">32336927</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandra M.S., Pratap V. COVİD-19: A Formidable Challenge to the Healthcare System. Res. Adv. Pharm. LifeSci. 2020;2:4–12. doi: 10.46610/RAPLS.2020.v02i02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.46610/RAPLS.2020.v02i02.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R., Lan Z., Ye J., Pang L., Liu Y., Wu W., Qin X., Guo Y., Zhang P. Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration. Front. Immunol. 2021;12:589095. doi: 10.3389/fimmu.2021.589095.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.589095</ArticleId><ArticleId IdType="pmc">PMC8115911</ArticleId><ArticleId IdType="pubmed">33995341</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P., Fajgenbaum D.C. Is severe COVID-19 a cytokine storm syndrome: A hyperinflammatory debate. Curr. Opin. Rheumatol. 2021;33:419–430. doi: 10.1097/BOR.0000000000000822.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000822</ArticleId><ArticleId IdType="pmc">PMC8373392</ArticleId><ArticleId IdType="pubmed">34264880</ArticleId></ArticleIdList></Reference><Reference><Citation>Montazersaheb S., Hosseiniyan Khatibi S.M., Hejazi M.S., Tarhriz V., Farjami A., Ghasemian Sorbeni F., Farahzadi R., Ghasemnejad T. COVID-19 infection: An overview on cytokine storm and related interventions. Virol. J. 2022;19:92. doi: 10.1186/s12985-022-01814-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-022-01814-1</ArticleId><ArticleId IdType="pmc">PMC9134144</ArticleId><ArticleId IdType="pubmed">35619180</ArticleId></ArticleIdList></Reference><Reference><Citation>de Fátima Cobre A., Alves A.C., Gotine A.R.M., Domingues K.Z.A., Lazo R.E.L., Ferreira L.M., Tonin F.S., Pontarolo R. Novel COVID-19 biomarkers identified through multi-omics data analysis: N-acetyl-4-O-acetylneuraminic acid, N-acetyl-L-alanine, N-acetyltriptophan, palmitoylcarnitine, and glycerol 1-myristate. Intern. Emerg. Med. 2024 doi: 10.1007/s11739-024-03547-1. Epub ahead of print .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-024-03547-1</ArticleId><ArticleId IdType="pubmed">38416303</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafqat A., Shafqat S., Salameh S.A., Kashir J., Alkattan K., Yaqinuddin A. Mechanistic Insights Into the Immune Pathophysiology of COVID-19; An In-Depth Review. Front. Immunol. 2022;13:835104. doi: 10.3389/fimmu.2022.835104.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.835104</ArticleId><ArticleId IdType="pmc">PMC8989408</ArticleId><ArticleId IdType="pubmed">35401519</ArticleId></ArticleIdList></Reference><Reference><Citation>Soy M., Keser G., Atagündüz P. Pathogenesis and treatment of cytokine storm in COVID-19. Turk. J. Biol. 2021;45:372–389. doi: 10.3906/biy-2105-37.</Citation><ArticleIdList><ArticleId IdType="doi">10.3906/biy-2105-37</ArticleId><ArticleId IdType="pmc">PMC8573840</ArticleId><ArticleId IdType="pubmed">34803441</ArticleId></ArticleIdList></Reference><Reference><Citation>Battaglini D., Lopes-Pacheco M., Castro-Faria-Neto H.C., Pelosi P., Rocco P.R.M. Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19. Front. Immunol. 2022;13:857573. doi: 10.3389/fimmu.2022.857573.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.857573</ArticleId><ArticleId IdType="pmc">PMC9091347</ArticleId><ArticleId IdType="pubmed">35572561</ArticleId></ArticleIdList></Reference><Reference><Citation>Aboughdir M., Kirwin T., Abdul Khader A., Wang B. Prognostic Value of Cardiovascular Biomarkers in COVID-19: A Review. Viruses. 2020;12:527. doi: 10.3390/v12050527.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12050527</ArticleId><ArticleId IdType="pmc">PMC7290838</ArticleId><ArticleId IdType="pubmed">32403242</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo Marin B., Aghagoli G., Lavine K., Yang L., Siff E.J., Chiang S.S., Salazar-Mather T.P., Dumenco L., Savaria M.C., Aung S.N., et al. Predictors of COVID-19 severity: A literature review. Rev. Med. Virol. 2021;31:1–10. doi: 10.1002/rmv.2146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2146</ArticleId><ArticleId IdType="pmc">PMC7855377</ArticleId><ArticleId IdType="pubmed">32845042</ArticleId></ArticleIdList></Reference><Reference><Citation>Menez S., Moledina D.G., Thiessen-Philbrook H., Wilson F.P., Obeid W., Simonov M., Yamamoto Y., Corona-Villalobos C.P., Chang C., Garibaldi B.T., et al. TRIKIC Consortium Investigators. Prognostic Significance of Urinary Biomarkers in Patients Hospitalized with COVID-19. Am. J. Kidney Dis. 2022;79:257–267.e1. doi: 10.1053/j.ajkd.2021.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2021.09.008</ArticleId><ArticleId IdType="pmc">PMC8542781</ArticleId><ArticleId IdType="pubmed">34710516</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrimanker I., Bhattarai S. StatPearls [Internet] StatPearls Publishing; Treasure Island, FL, USA: 2024. Electrolytes.</Citation><ArticleIdList><ArticleId IdType="pubmed">31082167</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagar N., Lohiya S. A Comprehensive Review of Chloride Management in Critically Ill Patients. Cureus. 2024;16:e55625. doi: 10.7759/cureus.55625.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.55625</ArticleId><ArticleId IdType="pmc">PMC10995984</ArticleId><ArticleId IdType="pubmed">38586759</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan X., Gao Y., Lai X., Wang B., Wu J., Yu X. Trimatch comparison of the prognosis of hypochloremia, normolchloremia and hyperchloremia in patients with septic shock. J. Formos. Med. Assoc. 2024 doi: 10.1016/j.jfma.2024.05.012. Epub ahead of print .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jfma.2024.05.012</ArticleId><ArticleId IdType="pubmed">38763858</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Yu Z., Zhu B., Ma J. The Association between the Hypochloremia and Mortality in Intensive Care Unit (ICU) Patients with Chronic Heart Failure. J. Vasc. Dis. 2023;2:188–196. doi: 10.3390/jvd2020013.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jvd2020013</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z., Xing C., Li T., Du L., Wang N. Hypochloremia is associated with increased risk of all-cause mortality in patients in the coronary care unit: A cohort study. J. Int. Med. Res. 2020;48:0300060520911500. doi: 10.1177/0300060520911500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0300060520911500</ArticleId><ArticleId IdType="pmc">PMC7218470</ArticleId><ArticleId IdType="pubmed">32338101</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh H.J., Kim S.J., Kim Y.C., Kim E.J., Jung I.Y., Oh D.H., Jeong S.J., Ku N.S., Han S.H., Choi J.Y., et al. An increased chloride level in hypochloremia is associated with decreased mortality in patients with severe sepsis or septic shock. Sci. Rep. 2017;7:15883. doi: 10.1038/s41598-017-16238-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-16238-z</ArticleId><ArticleId IdType="pmc">PMC5698440</ArticleId><ArticleId IdType="pubmed">29162885</ArticleId></ArticleIdList></Reference><Reference><Citation>Valga F., Monzón T., Vega-Diaz N., Ruiz-Santana S., Aladro S., Diallo-Saavedra R., De la Flor J.C., Rodriguez-Perez J.C. Hypochloremia associated with a greater incidence of pneumonia in chronic hemodialysis patients with COVID-19: A center’s experience. Nefrologia (Engl. Ed.) 2024;44:290–292. doi: 10.1016/j.nefroe.2024.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nefroe.2024.03.017</ArticleId><ArticleId IdType="pubmed">38631966</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Hou B., Liu J., Chen Y., Zhong P. Risk Factors Associated with Long-Term Hospitalization in Patients with COVID-19: A Single-Centered, Retrospective Study. Front. Med. 2020;7:315. doi: 10.3389/fmed.2020.00315.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.00315</ArticleId><ArticleId IdType="pmc">PMC7296106</ArticleId><ArticleId IdType="pubmed">32582749</ArticleId></ArticleIdList></Reference><Reference><Citation>Tezcan M.E., Dogan Gokce G., Sen N., Zorlutuna Kaymak N., Ozer R.S. Baseline electrolyte abnormalities would be related to poor prognosis in hospitalized coronavirus disease 2019 patients. New Microbes New Infect. 2020;37:100753. doi: 10.1016/j.nmni.2020.100753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmni.2020.100753</ArticleId><ArticleId IdType="pmc">PMC7462442</ArticleId><ArticleId IdType="pubmed">32904987</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira M.H., Abosamak M.F., Michael Henry B., Benoit S.W., Lippi G., Previdelli I. Longitudinal serum chloride as a marker for poor prognosis in severely ill COVID-19 patients: A joint model approach. Braz. J. Biom. 2024;42:88–99. doi: 10.28951/bjb.v42i1.670.</Citation><ArticleIdList><ArticleId IdType="doi">10.28951/bjb.v42i1.670</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46:846–848. doi: 10.1007/s00134-020-05991-x. Erratum in Intensive Care Med.
2020, 46, 1294–1297. https://doi.org/10.1007/s00134-020-06028-z .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-05991-x</ArticleId><ArticleId IdType="pmc">PMC7080116</ArticleId><ArticleId IdType="pubmed">32125452</ArticleId></ArticleIdList></Reference><Reference><Citation>Eraslan B.Z., Demirer E., Kıral N., Şener Cömert S. Is There a Relationship Between Serum Procalcitonin Level and Mortality and Disease Severity in Patients Diagnosed with COVID-19? J. Izmir Chest Hosp. 2023;37:122–127.</Citation></Reference><Reference><Citation>Grasselli G., Greco M., Zanella A., Albano G., Antonelli M., Bellani G., Bonanomi E., Cabrini L., Carlesso E., Castelli G., et al.  COVID-19 Lombardy ICU Network. Risk Factors Associated with Mortality Among Patients with COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Intern. Med. 2020;180:1345–1355. doi: 10.1001/jamainternmed.2020.3539. Erratum in: JAMA Intern. Med.
2021, 181 1021. https://doi.org/10.1001/jamainternmed.2021.1229 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.3539</ArticleId><ArticleId IdType="pmc">PMC7364371</ArticleId><ArticleId IdType="pubmed">32667669</ArticleId></ArticleIdList></Reference><Reference><Citation>Docherty A.B., Harrison E.M., Green C.A., Hardwick H.E., Pius R., Norman L., Holden K.A., Read J.M., Dondelinger F., Carson G., et al. ISARIC4C investigators. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. BMJ. 2020;369:m1985. doi: 10.1136/bmj.m1985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1985</ArticleId><ArticleId IdType="pmc">PMC7243036</ArticleId><ArticleId IdType="pubmed">32444460</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>